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Identification of COL4A5 defects in Alport’s syndrome by consist of a central collagenous domain of approximately
immunohistochemistry of skin. 1400 amino acid residues and noncollagenous (NC) do-
Background. The COL4A3-COL4A4-COL4A5 network in mains at the N- and C-terminal ends, called the 7S andthe glomerular basement membrane is affected in the inherited
the NC domain, respectively. A total of six type IV colla-renal disorder Alport’s syndrome (AS). Approximately 85%
gen chains, COL4A1 through COL4A6, with molecularof the AS patients are expected to carry a mutation in the
X-chromosomal COL4A5 gene and 15% in the autosomal weights ranging from 170 to 185 kDa, has been identified
COL4A3 and COL4A4 genes. The COL4A5 chain is also pres- [1–4]. Three a(IV)-chains form a triple helix (trimer),
ent in the epidermal basement membrane (EBM). It is pre-
which starts at the C-terminal NC domain. The N-termi-dicted that approximately 70% of the COL4A5 mutations pre-
nal 7S domains and the NC domains of different triplevent incorporation of this chain in basement membranes.
Methods. We investigated whether or not COL4A5 defects helices associate to form a “chicken-wire” shaped mesh-
could be detected by immunohistochemical analysis of the work. In the GBM, two collagen type IV networks have
EBM. Punch skin biopsies were obtained from 22 patients out been identified: the first consists of COL4A1 and COL4A2of 17 families and two biopsy specimens from healthy males
trimers, whereas the second network comprises COL4A3,were used as controls.
COL4A4, and COL4A5 chains [5, 6]. The COL4A6Results. In four cases with the COL4A5 frameshift or mis-
sense mutations, the COL4A5 chain was either lacking from chain is not present in the GBM [7]. Heterotrimers and
the EBM (male) or showed a focally negative pattern (female). homotrimers of COL4A1 and COL4A2 are ubiquitously
In three other patients with a COL4A5 missense mutation, a present in all basement membranes [6], whereas COL4A3,COL4A3 and a COL4A4 mutation, respectively, the COL4A5
COL4A4, COL4A5, and COL4A6 have a restricted tis-staining was normal. A (focally) negative EBM-COL4A5 staining
was found in three patients of six families with a diagnosis of AS sue distribution [8–12]. For example, in skin, only COL4A1,
and in one family of a group of four families with possible AS. COL4A2, COL4A5, and COL4A6 are found in the epi-
Conclusions. The (focal) absence of COL4A5 in the EBM dermal basement membrane (EBM) [7, 11].
of skin biopsy specimens can be used for fast identification
Alport’s syndrome (AS) [13] is a clinically heteroge-of COL4A5 defects. Combined with polymorphic COL4A5
nous, inherited disorder of the GBM that is characterizedmarkers, both postnatal and prenatal DNA diagnosis are possi-
ble in the family of the patient. by hematuria, proteinuria, progressive renal failure, and
high-tone sensorineural hearing loss [14–17]. Other clini-
cal features such as ocular abnormalities (lenticonus andType IV collagen, a multimeric protein composed of
retinal anomalies), diffuse esophagal or vulvar leiomyo-three a chains, forms a macromolecular network, which
matosis [18, 19], and macrothrombocytopenia [20, 21]is the main structural component of the glomerular base-
have also been described. Electron microscopic analysisment membrane (GBM). These type IV collagen chains
of renal biopsy specimens of AS patients shows an irregu-
lar thinning/thickening and multilamellation of the GBM.
1 See Editorial, p. 1575. In young patients, thinning of the GBM can be the only
symptom [22, 23]. The disorder is genetically heteroge-Key words: epidermal basement membrane, skin biopsy, inherited dis-
order, collagen chains, hematuria, progressive renal failure, proteinuria. nous, but a vast majority (85%) of Alport pedigrees
showed X-linked dominant inheritance (XL-AS) andReceived for publication June 25, 1998
was caused by mutations in the COL4A5 gene locatedand in revised form October 30, 1998
Accepted for publication October 30, 1998 in the Xq22-24 region [15, 24–26]. The estimated gene
frequency of AS is 1:5000 [27, 28]. Approximately 15% 1999 by the International Society of Nephrology
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of the pedigrees showed an autosomal recessive pattern sequently were air dried at room temperature for one
night before use. The monoclonal antibodies used inof inheritance of AS (AR-AS), caused by mutations in
the COL4A3 and COL4A4 genes at chromosome 2q35- this study required different treatment of the sections,
as indicated in Table 1. The sections were washed with37 [29, 30]. Autosomal dominant forms of AS have been
mapped to the COL4A3 and COL4A4 locus, but muta- phosphate buffered saline (PBS; 137 mm NaCl, 13 mm
Na2HPO4·2H2O, 3 mm KH2PO4 in demineralized water,tions have not yet been identified [31].
The heterogenous nature of AS and the huge size of pH 7.4) before the primary antibodies were applied.
After one hour of incubation in a humidified chamberthe type IV collagen genes involved hamper the mutation
analysis. As the COL4A5 protein is present both in the (room temperature), the sections were washed three
times with PBS (5 min each), and a secondary, fluores-GBM and in the EBM, we tested whether immunohisto-
chemical (IHC) analysis of skin biopsy specimens with cein isothiocyanate- or Texas Red-conjugated goat-anti-
mouse antibody (Southern Biotechnology Associatesantibodies against the COL4A5 chain could be used to
identify a COL4A5 gene defect. Approximately 70% of Inc. Birmingham, AL, USA) was applied. Sections were
incubated for 45 minutes at room temperature, washedthe reported mutations in the COL4A5 gene are pre-
dicted to lead to a truncated protein with an absent or three times (for 5 min each) with PBS, mounted in Mow-
iol (Hoechst, Frankfurt, Germany), and examined usingnonfunctional NC domain, which prevents triple-helix
formation and incorporation in the BM network. We a Zeiss microscope equipped with epifluorescence illumi-
nation optics. Skin biopsy specimens from normal indi-investigated patients with established type IV collagen
mutations, patients with the clinical diagnosis of AS, and viduals were included as the controls for each procedure.
The panel of monoclonal antibodies used in this studypatients with possible AS or familial benign hematuria
(FBH). (Table 1) can be used for the IHC analysis of both skin
biopsy and kidney biopsy specimens. In the case of IHC
of skin biopsy specimens, the panel includes two different
METHODS
procedures for COL4A5 staining (MAB5 on urea/glycine
Families/patients treated sections and Moab A7 for Tris/urea treated sec-
tions), one positive “control” staining for COL4A1Clinical criteria for AS were as described before [16].
DNA was extracted by a simple salting out procedure (MAB1), which indicates both the localization of the
EBM and the quality of the section, two negative controlfrom peripheral blood lymphocytes of patients and fam-
ily members [32]. stainings with primary antibodies against COL4A3
(MAB3, MCA-p1), and one control staining in which
Mutation analysis and polymorphic markers the primary antibody is replaced by PBS.
Individual exons of the COL4A5 gene of patients with
AS were screened for mutations by polymerase chain re-
RESULTS
action (PCR)-single strand conformation polymorphism
Staining the epidermal basement membrane(SSCP) analysis [33], using the Genephor system (Amers-
of patientsham Pharmacia Biotech, Uppsala, Sweden). In case of
mobility shift, direct sequence analysis of the exon was Sections of controls and patients were positive for
COL4A1 (Fig. 1d, g), with an uninterrupted stainingperformed using the Taq Dyedeoxye Terminator proto-
col from the manufacturer and the ABI 377 Automated pattern of the EBM, and negative for COL4A3 (Fig. 1e,
h) and the PBS control (Fig. 1f). The EBMs in theseSequencer (Applied Biosystems, Foster City, CA, USA).
Polymorphic microsatellite markers (DXS178; COL4A5- control sections were also positive for COL4A5 (Fig. 1i).
Identical results were obtained with the MAB5 and the2B6) were used as described before [30].
Moab A7 procedure. A male patient (A; Table 2) with a
Indirect immunofluorescence analysis and panel frameshift mutation in exon 49 (5005 1 1Gins10) was
of antibodies completely negative for COL4A5 (Fig. 1a), whereas a
female patient (B) with a frameshift mutation (3723delA;Punch skin biopsy specimens were obtained from 22
patients out of 17 families by a standard procedure, im- Table 2) in exon 39 showed a mosaic staining pattern
(Fig. 1b). The X-inactivation pattern resulted in focallymediately frozen in isopentane (2808C), and stored at
2808C or in liquid nitrogen. Two skin biopsy specimens negative and positive parts of the EBM. Two male pa-
tients (C, D) with missense mutations resulting in glycineof healthy males were used as control specimens. The
specimens were embedded in OCTTM (10.24% polyvinyl substitutions (C: exon 31, 2808G . A, Gly869Glu; D:
exon 23,1782G . A, Glu527Gly) showed a negative stain-alcohol, 4.26% polyethylene glycol, 85.5% nonreactive
ingredients; Tissue Tec, Miles, Naperville, USA). Five ing pattern, whereas a male patient (E) with a missense
mutation (exon 7, 588G . A, Gly129Glu) showed a nor-mm cryosections were taken up on glass slides (Superfrost
plus; Menzell Gla¨ser, Braunschweig, Germany) that sub- mal staining pattern (Fig. 1c). The EBM of a female
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Table 1. Monoclonal antibodies, section pretreatment and references
Antigen Antibody Dilution Section treatment Reference
COL4A1 MAB1 1:10–25 10 min acetone 2208C [12, 38, 39]
COL4A3 MAB3 1:10–25 10 min acetone 2208C [20, 38, 39]
COL4A3 MCA-pl u.d.–1:5 15 min cold Tris/urea [40]
COL4A5 MAB5 1:10–25 10 min acetone 2208C 1 5 min cold glycine/urea [12, 38, 39]
COL4A5 Moab A7 u.d.–1:5 15 min cold Tris/urea [41]
Abbreviation u.d. is undiluted culture supernatant.
Fig. 1. Immunohistochemistry of skin biopsies of AS patients (a–e) and normal skin (f–i). Sections were stained with monoclonal antibodies
against COL4A5 (a, b, c, i), COL4A1 (d, g), COL4A3 (e, h) or were incubated with PBS instead of a monoclonal antibody (f; negative control).
Bar indicates 50 mm.
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Table 2. Immunohistochemistry of the epidermal basement membrane (EBM) in patients with Alport’s syndrome (AS) and possible AS
Clinical COL4A5 Position mutation Nature of Effect on
Family N M/F diagnosis staining gene/exon mutation coding sequence Reference
I. Patients with established mutations
A 1 M AS negative COL4A5/49 5005 1 1Gins10 splice site [27]
B 1 F AS mosiac COL4A5/39 3723delA frame shift this study
C 1 M AS negative COL4A5/31 2808G.A Gly869Glu this study
D 1 M AS negative COL4A5/23 1782G.A Gly527Glu this study
D 1 F AS mosiac
E 1 M AS positive COL4A5/07 588G.A Gly129Glu [34, 35]
F 1 F AS positive COL4A3/05 4414del5/ frame shift & stop
(homozygote) 4419del5 33 codons downstream [36]
G 1 M FBH positive COL4A4 2898G.A Gly897Glu [37]
II. Patients diagnosed AS
H 2 M AS positive — — — —
I 1 M AS positive — — — —
J 1 M AS negative — — — —
K 1 M AS negative — — — —
L 1 F AS positive — — — —
III. Possible AS & FBH patients
M 2 M possible AS negative — — — —
N 1 M possible AS positive — — — —
O 1 M possible AS positive — — — —
P 1 M possible AS positive — — — —
Q 1 M FBH positive — — — —
carrier (D) showed a mosaic staining pattern. These data, pattern of the EBM. No false diagnosis was obtained in
the AR-AS and FBH cases (F, G, Q), and the COL4A5summarized in Table 2 part I, indicate that IHC of the
EBM for COL4A5 is suitable to identify COL4A5 muta- staining of the EBM was normal in all three patients.
The results obtained in the group of possible AS familiestions that prevent incorporation of the COL4A5 chain
in type IV collagen BMs. The patients with mutations (M–P) did not contribute to the overall detection rate
because the diagnosis of AS was not clinically certain.in COL4A3 (F) and COL4A4 (G) showed a normal
COL4A5 staining pattern in the EBM.
Family investigationsSections of skin biopsy specimens of six patients with
the diagnosis AS were stained for COL4A5 (H–L; Table Immunohistochemical analysis of skin biopsies of male
patients in combination with marker analysis can be used2, part II). The diagnosis was based on the presence of
at least three of the four clinical criteria for AS [16]. The to determine the COL4A5 risk haplotype in a family
without the necessity of performing extensive linkagefamilial cases were likely X linked, based on the presence
of less severely affected female patients, exclusion of the analysis. In case of a female patient, a second patient
must to be available to determine the phase of the riskCOL4A3/COL4A4 locus, and if the family was large
enough, on linkage analysis for the COL4A5 locus. The haplotype. Subsequently, postnatal and prenatal investi-
gations can be offered in such a family. If a de novosections of patients in two families (J, K; N 5 2) were
negative for the COL4A5 chain. Patients in three other mutation is suspected, then additional skin biopsies have
to be performed in family members who are at risk.(H, I, L; N 5 4) had a normal COL4A5 staining pattern
in the EBM. Skin biopsy specimens of five persons from Recently, we used this approach in two families (D and
J; Fig. 2). DNA and skin biopsies were obtained in familyfour families (M–P) with an ambiguous diagnosis of AS
were also investigated. One patient (M) showed a nega- D from a carrier (II:2) and her severely affected brother
(II:1). The carrier turned out be informative for markertive staining for COL4A5. This result was confirmed in
a second patient in this family. The other three patients DXS178, and a prenatal diagnosis could be offered on
the basis of this marker. In the second family (J), a(N–P) showed a normal COL4A5 staining pattern. The
skin biopsy specimen of a FBH patient (Q) was also severely affected male patient (II:1) was tested with his
asymptomatic sister (II:2) and mother (I:2). The EBMnormal, and COL4A5 was present in the EBM (Table
2, parts I and III). of the patient was negative for COL4A5, whereas the
EBM of both women was positive. The sister did notCumulative results of all families with an evident diag-
nosis AS indicate that in 6 (A–D, J, K) out of 11 unrelated inherit the risk haplotype. The IHC indicated that most
likely a de novo COL4A5 mutation had occurred inAlport patients (A–F and H–L), a COL4A5 defect was
detectable by a negative or mosaic COL4A5 staining the male patient. Skewed X inactivation in the mother
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of the skin that in at least 50 to 60% of the AS patients
[42]. A skin biopsy is less invasive and easier to perform
than a kidney biopsy. Therefore, combining the criteria
for AS, as Flinter et al defined [16], with IHC of the skin
can be the first step in the diagnostic protocol of AS.
First, we tested the EBM of patients with characterized
mutations, either in the COL4A5, COL4A3, or COL4A4
gene. The epitopes of the monoclonal antibodies used
were located in the NC domain at the carboxy-terminal
part of the type IV collagen chains. The patients with a
COL4A5 frameshift mutation showed a negative (male;
A) or mosaic negative (female; B) pattern, indicating
that the resulting truncated chain could not be incorpo-
rated (or detected) in the COL4A5-COL4A6 network.
It has been reported that in case the a5(IV) chain is
absent from the EBM, the a6(IV) chain is also absent
[7, 44, 45] and the entire COL4A5-COL4A6 network in
these patients might be (focally) absent. In the male
patient, the mutation (COL4A5/exon 49) occurred in
the NC domain itself. Therefore, the negative staining
of the EBM in this patient could be due to the absence
of the entire network or to the absence (or the alteration)
of the epitopes in the NC domain. In this case, as well
as in similar cases with mutations in the COL4A5 NC
domain, it would be appropriate to test the EBM with
monoclonal antibodies against COL4A6 to check whether
there is a COL4A5-COL4A6 network present. We have
hypothesized for this patient (A) that the remaining part
of the COL4A5 NC domain could be sufficient for inte-Fig. 2. Family investigations using immunohistochemistry of skin
biopsy specimens and polymorphic COL4A5 markers: pedigrees of gration of this a chain in the COL4A3-COL4A4-COL4A5
families D and J. Symbols are: (h) unaffected male; (j) affected male; network, which would explain the relatively mild course(s) unaffected female; (d) affected female; (/) deceased; (e) fetus.
of the disease [34, 35].The abbreviation nd means not determined.
The EBM of three male patients with COL4A5 mis-
sense mutations (C–E) showed either a negative (C, D)
or a positive (E) staining pattern. The mutations in exon
cannot be entirely excluded, although we did not ob- 31 (C) and exon 23 (D), resulting in glycine into glutamic
served this in our series of female patients. acid substitutions, are located in the collagenous domain
of COL4A5 and interrupt the characteristic Gly-X-Y
repeat. Why these mutations lead to the absence of theDISCUSSION
COL4A5-COL4A6 network and not just result in an
Mutations in the X-chromosomal gene coding for altered triple helix is not clear. Further investigations
COL4A5, a component of the heterogenic type IV colla- are necessary to establish the exact effect of these muta-
gen network of the GBM, are expected to be involved tions and will probably allow further discrimination in
in approximately 85% of all cases of AS. Thus far, no the group of predicted glycine substitutions. The patient
other renal disease with a mutation in the COL4A5 gene (E) with the missense mutation in COL4A5/exon 7 was
has been reported, and no other X-linked gene has been COL4A5 positive, indicating that this amino acid substi-
found solely mutated in AS. A large part of the COL4A5 tution did not prevent incorporation in the COL4A5-
mutations is predicted to prevent integration into type COL4A6 network and that the epitopes of the two
IV collagen containing BMs, such as the GBM and the monoclonal antibodies to COL4A5 were present. As
EBM [12, 42]. IHC analysis of skin biopsy specimens as expected [39], the two patients with established muta-
a rapid method for the diagnosis of XL-AS has been tions in COL4A3 (F) and COL4A4 (G) showed a normal
described before, but so far no studies on skin biopsy positive COL4A5 staining in the EBM.
specimens of patients with characterized mutations have Skin biopsy specimens of patients from two families
been published [7, 10, 41, 43–46]. It is estimated the with AS (J, K) showed a negative or mosaic staining
pattern, indicating the presence of a COL4A5 mutation.underlying COL4A5 mutation can be detected by IHC
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A positive COL4A5 staining in the other three families mutations, making mutation analysis less laborious.
However, because of the repetitive and conserved amino(H, I, L) does not exclude a COL4A5 defect. Definite
proof for the involvement of COL4A5 has to come in acid sequence of the collagen type IV chains, it will
be very difficult to generate chain specific monoclonalthese cases from mutation analysis. From our group of
four families with possible AS (M–P), one family (M) antibodies to these regions. Antisera against COL4A6,
the second component of the COL4A5-COL4A6 net-was identified as having a COL4A5 mutation.
Immunohistochemical analysis of the EBM can iden- work in the EBM, could indicate whether the absence of
tify COL4A5 defects in approximately 50 to 60% of the a COL4A5 signal in the EBM is caused by the complete
patients with Alport’s syndrome [42], which is compati- absence of this network (both COL4A5 and COL4A6
ble with our results, although only a small group of pa- negative) [7] or by the absence of the epitope in the
tients has been tested. The results of our study were COL4A5 NC domain (COL4A5 negative and COL4A6
compared with the cumulative results of seven previous positive). This may have implications for clinical mani-
studies [7, 10, 41, 43–46]. In these studies, involving 30 festations of the genetic defect. Apart from AS with
AS families, 32 of 36 male patients and 32 of 34 female leiomyomatosis, thus far no other renal diseases have
patients were detected by IHC. All 25 XL-AS families been reported that are linked with COL4A6 mutations.
and three out of five de novo AS families [43] were A mutation in COL4A5 can have different effects in
identified. In 12 of these families, nonaffected members the COL4A3-COL4A4-COL4A5 network of the GBM
were tested, and all EBMs were COL4A5 positive. The compared with the COL4A5-COL4A6 network of the
detection rate in the AS families in our study (6 out of EBM [46]. This is also a possible explanation for not
11 families) is lower than the overall detection rate of detecting certain COL4A5 mutations by immunostain-
these seven studies. Because our study almost exclusively ing of the skin. The presence of COL4A5 in the EBM
included the probands of the families, and the other in combination with the absence of this chain in the
studies (a) did not include data of XL-AS families that GBM can also be the result of mutations in the COL4A3
were not detected by IHC and (b) included more than or COL4A4 genes in autosomal AS. The absence of
one patient per family, there is a bias in the results from COL4A5 in the EBM is a clear indication for XL-AS,
the literature. Gubler et al reported COL4A5-positive but the presence of COL4A5 does not exclude XL-AS,
EBMs in patients from four AR-AS families [39]. The nor does it unequivocally determine the patient to have
EBM of the proband of our AR-AS family (F) is also AR-AS.
COL4A5 positive. Nakanishi et al described IHC of the In summary, the combination of clinical data and im-
EBM in a group of four possible AS families, but munostaining of skin biopsies can identify a large portion
COL4A5-negative EBMs were not detected [43]. The of AS patients, saving these patients from undergoing a
data show that the detection of both male patients and kidney biopsy. This approach is fast and does not require
female carriers by skin biopsy specimen analysis is a the clinical data and/or cooperation of several family
fast and reliable method to diagnose COL4A5 defects members (as is the case with linkage analysis), and the
causing XL-AS. The score of IHC analysis of the EBM, percentage of mutations detected is at least equal to the
an in vivo protein truncation test, is comparable with the percentage of mutation detection by PCR-SSCP analysis.
score of mutation detection by PCR-SSCP [27]. Mutation Because IHC localizes the gene defect to COL4A5, it
detection of COL4A5 is slow, laborious, and expensive can be used in combination with COL4A5-linked DNA
because all 51 exons have to be screened individually, markers to enable postnatal and prenatal diagnosis in
whereas skin biopsy analysis is fast, less expensive, and suitable families and to identify de novo mutations.
less laborious. Recently, Nakanishi et al studied the cor-
relation between the severity of the disease and the de- ACKNOWLEDGMENTS
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